CAS: 22126-16-5; 4,6-Dimethylpyrimidine-2-Carbonitrile

该化合物是一种多用途有机化合物,在合成药物和农用化学物方面有重要应用,具有很高的纯度和稳定性,为生产活性药物成分提供了可靠的起始材料,其独特的结构特征提供了极好的回动性,促进了高效的化学转化,该化合物因其合成效用和在新发现的药物中的潜力而备受高度重视.

结构式图片

相似化合物

77768-02-6 14331-54-5 64571-34-2

上下游产品

CAS号7677-24-9 三甲基氰硅烷 | CAS号13435-20-6 氰化四乙基铵 | CAS号77767-94-3 Trimethyl-2-(4,... | CAS号151-50-8 氰化钾 | CAS号4472-44-0 2-氯-4,6-二甲基嘧啶 | CAS号14001-61-7 2-甲氧基-4,6-二甲基嘧啶 | CAS号1558-17-4 4,6-二甲基嘧啶 | CAS号27427-89-0 4,6-二甲基嘧啶-2-羧酸甲酯 | CAS号73937-25-4 2-Pyrimidinecar... | CAS号60420-76-0 2-嘧啶羧酸,4,6-二甲基-... | CAS号64571-50-2 Ethanone,1-(4,6...

合成工艺路线路线简述

  • 合成目标产物 4,6-Dimethylpyrimidine-2-Carbonitrile 主要起始原料 Pyrimidine, 4,6-Dimethyl-, 1-Oxide (6Ci,7Ci,8Ci,9Ci) And Trimethylsilyl Cyanide
  • (文献来源)合成步骤主要原料 Pyrimidine, 4,6-Dimethyl-, 1-Oxide (6Ci,7Ci,8Ci,9Ci) 和 Trimethylsilyl Cyanide
📜氰化钾,(4,6-Dimethylpyrimid-2'-yl)-Trimethylammonium Chloride置于乙酰胺体系中,化学反应生成4,6-二甲基嘧啶-2-甲腈
参考文献:Heteroarylierungen Mit Quartrsubstituierten Pyrimidinsalzen
标题:Heteroarylierungen Mit Quartrsubstituierten Pyrimidinsalzen
摘要:
Doi:10.1007/bf00917846

海关参考信息

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

合成参考文献


参考文献:10.1126/science.abo7201
摘要:Boby ML, Fearon D, Ferla M, Filep M, Koekemoer L, Robinson MC; COVID Moonshot Consortium‡, Chodera JD, Lee AA, London N, von Delft A, von Delft F, Achdout H, Aimon A, Alonzi DS, Arbon R, Aschenbrenner JC, Balcomb BH, Bar-David E, Barr H, Ben-Shmuel A, Bennett J, Bilenko VA, Borden B, Boulet P, Bowman GR, Brewitz L, Brun J, Bvnbs S, Calmiano M, Carbery A, Carney DW, Cattermole E, Chang E, Chernyshenko E, Clyde A, Coffland JE, Cohen G, Cole JC, Contini A, Cox L, Croll TI, Cvitkovic M, De Jonghe S, Dias A, Donckers K, Dotson DL, Douangamath A, Duberstein S, Dudgeon T, Dunnett LE, Eastman P, Erez N, Eyermann CJ, Fairhead M, Fate G, Fedorov O, Fernandes RS, Ferrins L, Foster R, Foster H, Fraisse L, Gabizon R, García-Sastre A, Gawriljuk VO, Gehrtz P, Gileadi C, Giroud C, Glass WG, Glen RC, Glinert I, Godoy AS, Gorichko M, Gorrie-Stone T, Griffen EJ, Haneef A, Hassell Hart S, Heer J, Henry M, Hill M, Horrell S, Huang QYJ, Huliak VD, Hurley MFD, Israely T, Jajack A, Jansen J, Jnoff E, Jochmans D, John T, Kaminow B, Kang L, Kantsadi AL, Kenny PW, Kiappes JL, Kinakh SO, Kovar B, Krojer T, La VNT, Laghnimi-Hahn S, Lefker BA, Levy H, Lithgo RM, Logvinenko IG, Lukacik P, Macdonald HB, MacLean EM, Makower LL, Malla TR, Marples PG, Matviiuk T, McCorkindale W, McGovern BL, Melamed S, Melnykov KP, Michurin O, Miesen P, Mikolajek H, Milne BF, Minh D, Morris A, Morris GM, Morwitzer MJ, Moustakas D, Mowbray CE, Nakamura AM, Neto JB, Neyts J, Nguyen L, Noske GD, Oleinikovas V, Oliva G, Overheul GJ, Owen CD, Pai R, Pan J, Paran N, Payne AM, Perry B, Pingle M, Pinjari J, Politi B, Powell A, Pšenák V, Pulido I, Puni R, Rangel VL, Reddi RN, Rees P, Reid SP, Reid L, Resnick E, Ripka EG, Robinson RP, Rodriguez-Guerra J, Rosales R, Rufa DA, Saar K, Saikatendu KS, Salah E, Schaller D, Scheen J, Schiffer CA, Schofield CJ, Shafeev M, Shaikh A, Shaqra AM, Shi J, Shurrush K, Singh S, Sittner A, Sjö P, Skyner R, Smalley A, Smeets B, Smilova MD, Solmesky LJ, Spencer J, Strain-Damerell C, Swamy V, Tamir H, Taylor JC, Tennant RE, Thompson W, Thompson A, Tomásio S, Tomlinson CWE, Tsurupa IS, Tumber A, Vakonakis I, van Rij RP, Vangeel L, Varghese FS, Vaschetto M, Vitner EB, Voelz V, Volkamer A, Walsh MA, Ward W, Weatherall C, Weiss S, White KM, Wild CF, Witt KD, Wittmann M, Wright N, Yahalom-Ronen Y, Yilmaz NK, Zaidmann D, Zhang I, Zidane H, Zitzmann N, Zvornicanin SN. Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors. Science. 2023 Nov 10;382(6671):eabo7201.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知